Pharmacotherapy for irritable bowel syndrome

Michael Camilleri, Alexander C. Ford

Research output: Contribution to journalReview articlepeer-review


Irritable bowel syndrome (IBS) is a disorder of the brain-gut axis; the pathophysiological mechanisms include altered colonic motility, bile acid metabolism, neurohormonal regulation, immune dysfunction, alterations in the epithelial barrier and secretory properties of the gut. This article reviews the mechanisms, efficacy, and safety of current pharmacotherapy, and medications that are in phase III trials for the treatment of IBS. There remains a significant unmet need for effective treatments-particularly for the pain component of IBS-although the introduction of drugs directed at secretion, motility and a non-absorbable antibiotic provide options for the bowel dysfunction in IBS.

Original languageEnglish (US)
Article number101
JournalJournal of Clinical Medicine
Issue number11
StatePublished - Nov 2017


  • Analgesia
  • Constipation
  • Diarrhea
  • Pain
  • Viscera

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Pharmacotherapy for irritable bowel syndrome'. Together they form a unique fingerprint.

Cite this